RETRACTED ARTICLE: Honokiol suppresses the development of post-ischemic glucose intolerance and neuronal damage in mice

Harada, Shinichi; Kishimoto, Maya; Kobayashi, Motoyasu; Nakamoto, Kazuo; Fujita-Hamabe, Wakako; Chen, Hwei-Hsien; Chan, Ming‐Huan; Tokuyama, Shogo

doi:10.1007/s11418-011-0623-x

Cited by 21 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because adiponectin is a protein, orally administered adiponectin cannot be absorbed [87]. Currently, adiponectin is administered via intravenous or intraperitoneal injection [87,88]. The blood-brain barrier (BBB) is formed by endothelial cells and tight junctions, which form capillary walls.…”

Section: Discussion and Future Prospectsmentioning

confidence: 99%

The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases

Yang

Jiang

et al. 2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

View full text Add to dashboard Cite

Section: Discussion and Future Prospectsmentioning

confidence: 99%

The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases

Yang

Jiang

et al. 2015

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

View full text Add to dashboard Cite

“…As AMPK exists as different heterotrimeric compound consisting of various isoforms, it is conceivable that different contexts of stimulation may lead to disparate consequences. There are other phytochemicals that have been reported to activate AMPK, such as Honokiol (104), that have been shown to have consequences other than cancer prevention. Thus, it seems that AMPK can be used not only as a chemotherapeutic agent but also to protect from injury, diabetes, or inflammatory diseases.…”

Section: Conclusion and Future Considerationsmentioning

confidence: 99%

Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy

Kim¹,

He²

2013

Front. Oncol.

126

109

View full text Add to dashboard Cite

Despite the advances in biomedical research and clinical applications, cancer remains a leading cause of death worldwide. Given the limitations of conventional chemotherapeutics, including serious toxicities and reduced quality of life for patients, the development of safe and efficacious alternatives with known mechanism of action is much needed. Prevention of cancer through dietary intervention may hold promise and has been investigated extensively in the recent years. AMP-activated protein kinase (AMPK) is an energy sensor that plays a key role in the regulation of protein and lipid metabolism in response to changes in fuel availability. When activated, AMPK promotes energy-producing catabolic pathways while inhibiting anabolic pathways, such as cell growth and proliferation – thereby antagonizing carcinogenesis. Other anti-cancer effects of AMPK may include promoting autophagy and DNA repair upon UVB damage. In the last decade, interest in AMPK has grown extensively as it emerged as an attractive target molecule for cancer prevention and treatment. Among the latest developments is the activation of AMPK by naturally occurring dietary constituents and plant products – termed phytochemicals. Owing to their efficacy and safety, phytochemicals are considered as an alternative to the conventional harmful chemotherapy. The rising popularity of using phytochemicals for cancer prevention and therapy is supported by a substantial progress in identifying the molecular pathways involved, including AMPK. In this article, we review the recent progress in this budding field that suggests AMPK as a new molecular target in the prevention and treatment of cancer by phytochemicals.

show abstract

“…The Infarct size coefficient of variation (in the total 500 control groups9101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110…”

Section: Resultsmentioning

confidence: 99%

Method parameters’ impact on mortality and variability in mouse stroke experiments: a meta-analysis

Ingberg

Dock

Theodorsson

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Although hundreds of promising substances have been tested in clinical trials, thrombolysis currently remains the only specific pharmacological treatment for ischemic stroke. Poor quality, e.g. low statistical power, in the preclinical studies has been suggested to play an important role in these failures. Therefore, it would be attractive to use animal models optimized to minimize unnecessary mortality and outcome variability, or at least to be able to power studies more exactly by predicting variability and mortality given a certain experimental setup. The possible combinations of methodological parameters are innumerous, and an experimental comparison of them all is therefore not feasible. As an alternative approach, we extracted data from 334 experimental mouse stroke articles and, using a hypothesis-driven meta-analysis, investigated the method parameters’ impact on infarct size variability and mortality. The use of Swiss and C57BL6 mice as well as permanent occlusion of the middle cerebral artery rendered the lowest variability of the infarct size while the emboli methods increased variability. The use of Swiss mice increased mortality. Our study offers guidance for researchers striving to optimize mouse stroke models.

show abstract

RETRACTED ARTICLE: Honokiol suppresses the development of post-ischemic glucose intolerance and neuronal damage in mice

Cited by 21 publications

References 35 publications

The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases

The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases

Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy

Method parameters’ impact on mortality and variability in mouse stroke experiments: a meta-analysis

Contact Info

Product

Resources

About